Consequently, circulating ECFCs will be again recruited to the tumor site, in which they will be able to proliferate and re-establish the vascular network in spite of the presence of anti-VEGF drugs as they are not sensitive to VEGF [13, 23]. This evidence concerns the gene VEGFA and neoplasm.